AR126578A1 - Anticuerpos anti-ccr8 - Google Patents

Anticuerpos anti-ccr8

Info

Publication number
AR126578A1
AR126578A1 ARP220101985A ARP220101985A AR126578A1 AR 126578 A1 AR126578 A1 AR 126578A1 AR P220101985 A ARP220101985 A AR P220101985A AR P220101985 A ARP220101985 A AR P220101985A AR 126578 A1 AR126578 A1 AR 126578A1
Authority
AR
Argentina
Prior art keywords
seq
cdr
antibody
ccr8
set forth
Prior art date
Application number
ARP220101985A
Other languages
English (en)
Spanish (es)
Inventor
Andrew J Mccluskey
Paustian Amanda M Schmidt
Jane Seagal
Julie L Wilsbacher
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR126578A1 publication Critical patent/AR126578A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP220101985A 2021-07-27 2022-07-27 Anticuerpos anti-ccr8 AR126578A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27

Publications (1)

Publication Number Publication Date
AR126578A1 true AR126578A1 (es) 2023-10-25

Family

ID=82898810

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101985A AR126578A1 (es) 2021-07-27 2022-07-27 Anticuerpos anti-ccr8

Country Status (27)

Country Link
US (1) US11639393B2 (cg-RX-API-DMAC7.html)
EP (2) EP4491635A3 (cg-RX-API-DMAC7.html)
JP (2) JP7638935B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250135339A (cg-RX-API-DMAC7.html)
CN (1) CN117425677A (cg-RX-API-DMAC7.html)
AR (1) AR126578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022317803A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024837A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220121A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015915A2 (cg-RX-API-DMAC7.html)
DK (1) DK4214240T3 (cg-RX-API-DMAC7.html)
ES (1) ES2995868T3 (cg-RX-API-DMAC7.html)
FI (1) FI4214240T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241561T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069018T2 (cg-RX-API-DMAC7.html)
IL (2) IL319478A (cg-RX-API-DMAC7.html)
LT (1) LT4214240T (cg-RX-API-DMAC7.html)
MX (1) MX2023014154A (cg-RX-API-DMAC7.html)
PL (1) PL4214240T3 (cg-RX-API-DMAC7.html)
PT (1) PT4214240T (cg-RX-API-DMAC7.html)
RS (1) RS66234B1 (cg-RX-API-DMAC7.html)
SA (1) SA523451582B1 (cg-RX-API-DMAC7.html)
SI (1) SI4214240T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400483T1 (cg-RX-API-DMAC7.html)
TW (2) TWI920354B (cg-RX-API-DMAC7.html)
WO (1) WO2023010054A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309516B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
PT3431105T (pt) 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US20250019449A1 (en) 2020-03-05 2025-01-16 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
AU2021244200A1 (en) 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders

Also Published As

Publication number Publication date
CA3220121A1 (en) 2023-02-02
TWI920354B (zh) 2026-04-01
CN117425677A (zh) 2024-01-19
LT4214240T (lt) 2024-11-25
US11639393B2 (en) 2023-05-02
EP4491635A2 (en) 2025-01-15
SA523451582B1 (ar) 2025-04-26
ZA202309516B (en) 2025-03-26
HUE069018T2 (hu) 2025-02-28
IL307533A (en) 2023-12-01
KR20240067052A (ko) 2024-05-16
HRP20241561T1 (hr) 2025-02-14
JP2025081477A (ja) 2025-05-27
SI4214240T1 (sl) 2025-02-28
US20230048553A1 (en) 2023-02-16
DK4214240T3 (da) 2024-11-18
AU2022317803A1 (en) 2023-10-26
EP4491635A3 (en) 2025-04-02
JP7638935B2 (ja) 2025-03-04
JP2023018678A (ja) 2023-02-08
ES2995868T3 (en) 2025-02-11
PL4214240T3 (pl) 2025-01-07
BR112023024837A2 (pt) 2024-02-20
FI4214240T3 (fi) 2024-11-14
EP4214240B1 (en) 2024-10-09
TW202611084A (zh) 2026-03-16
TW202321304A (zh) 2023-06-01
PT4214240T (pt) 2024-11-25
EP4214240A1 (en) 2023-07-26
CO2023015915A2 (es) 2023-12-11
IL307533B2 (en) 2025-08-01
WO2023010054A1 (en) 2023-02-02
SMT202400483T1 (it) 2025-01-14
IL319478A (en) 2025-05-01
MX2023014154A (es) 2024-05-14
RS66234B1 (sr) 2024-12-31
KR102860769B1 (ko) 2025-09-18
IL307533B1 (en) 2025-04-01
KR20250135339A (ko) 2025-09-12

Similar Documents

Publication Publication Date Title
AR117727A1 (es) Anticuerpos que se unen a cd3
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
MX2024009976A (es) Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso.
JOP20210013A1 (ar) تركيبات جسم مضاد fcrn
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
PE20121494A1 (es) Anticuerpos anti notch-1
AR130550A1 (es) Anticuerpo anti-il-1r3 humanizado y métodos de uso
AR124558A1 (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco
FI4214240T3 (fi) Ccr8-vasta-aineita
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
AR129991A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
AR123671A1 (es) Anticuerpo fn14 anti-humano
PE20212269A1 (es) Anticuerpos anti-trem1 y metodos relacionados
AR120430A1 (es) Células car-t dirigidas a epha3 para el tratamiento de tumores
AR121441A1 (es) Anticuerpos anti-axl y composiciones
AR130144A1 (es) Proteínas de unión a nkg2d, cd16 y ceacam5
AR123855A1 (es) Anticuerpos anti-mertk conjugados con peg y métodos de uso
AR133999A1 (es) Conjugado anticuerpo-fármaco (adc) dirigido a la nectina 4 y que comprende una carga útil de exatecán
SA523441069B1 (ar) EphA4 جسم مضاد لـ